

Kamlesh C. Agarwal and Edward E. Knaus*


Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta,
Edmonton, Alberta, T6G 2N8, Canada

Received April 9, 1986

The Darzen's reaction of 2-(3-)pyridinecarboxaldehydes **5** with chloroacetonitrile yielded a mixture of stereoisomers *cis*-**6** and *trans*-3-(pyridinyl)-2,3-epoxypropionitriles **7** in a ratio of approximately 1:1. Oxidation of *cis*-**6** and *trans*-**7** afforded the corresponding *cis*-**8** and *trans*-3-(1-oxido-2-pyridinyl)-2,3-epoxypropionitriles **9** in good yield. The reaction of **8a** and **9a** with pyrrolidine at 25° gave the respective *threo*-**10** and *erythro*-2-(1-pyrrolidino)-3-hydroxy-3-(1-oxido-2-pyridinyl)propionitrile (**11**). A number of selected compounds (**7-9a-b**) were found to be inactive in the P388 Lymphocytic screen.


J. Heterocyclic Chem., **24**, 15 (1987).

There has recently been a considerable degree of pharmacological interest in Mannich bases **1** [1] and arylsulfonylhydrazones of 2-formylpyridine *N*-oxide **2** [2] as anti-neoplastic agents. The antineoplastic activity of **2** has been attributed to the potent alkylating species 1-oxido-2-pyridin-2-yl diazomethane **3** resulting from intramolecular abstraction of the nitrogen proton by the *N*-oxide group followed by release of the arylsulfonic acid [3]. It has been reported that the β -carbon of α,β -epoxy sulfoxides **4** is highly reactive towards nucleophiles yielding dialkyl ketones or aldehydes in high yields under mild conditions [4]. In an earlier report, we described the synthesis of 1-[1-oxido-2-(3,4-)pyridinyl]-2-methyloxiranes and their reactions with sulfur, oxygen and nitrogen nucleophiles [5]. It was therefore of interest to extend this study to include activated oxiranes, which may react with cellular thiols, for evaluation as antitumor agents. We now describe the synthesis of some 3-(pyridinyl)-2,3-epoxypropionitriles and their reaction with the nitrogen nucleophile pyrrolidine.




The Darzen's reaction of 2-pyridinecarboxaldehyde (**5a**) with chloroacetonitrile in the presence of potassium *t*-butoxide in *t*-butyl alcohol afforded a mixture of stereoisomers *cis*-**6a** (23%) and *trans*-3-(2-pyridinyl)-2,3-epoxypropionitrile (**7a**, 27%) (Scheme I). A similar reaction of **5b** yielded *cis*-**6b** (17%) and *trans*-**7b** (20%). Oxidation of

the 2,3-epoxypropionitriles **6** and **7** with *m*-chloroperbenzoic acid gave the respective *cis*-**8** and *trans*-**9** *N*-oxide analogs which were routinely purified by elution from a neutral alumina column to remove excess *m*-chloroperbenzoic acid and *m*-chlorobenzoic acid.




The stereospecific reaction of *cis*-**8a** and *trans*-3-(1-oxido-2-pyridinyl)-2,3-epoxypropionitrile (**9a**) with nucleophiles as amines afforded the respective *threo* (2*R*,3*R*/2*S*,3*S*) and *erythro* (2*R*,3*S*/2*S*,3*R*) β -aminoalcohol diastereoisomers [5,6] (Scheme II). Thus reaction of *cis*-**8a** with pyrrolidine at 25° gave *threo*-2-(1-pyrrolidino)-3-hydroxy-3-(1-oxido-2-pyridinyl)propionitrile (**10**, 86%) whereas reaction of *trans*-**9a** gave rise to *erythro*-**11** (82%). The amination reaction was regiospecific since no product arising from attack by pyrrolidine at C-3 of **8a** or **9a** was detected [5].

The antineoplastic activity of compounds containing the α,β -unsaturated structural moiety has been attributed to their reaction with cellular nucleophiles [7-9]. Nucleophilic attack by anions on α,β -unsaturated carbonyl compounds is known as the Michael reaction and has been studied extensively primarily due to its synthetic usefulness [1]. It was expected that oxiranes having elec-



tron attracting cyano and pyridinyl (**6-7**) or 1-oxidopyridinyl (**8-9**) substituents would be highly activated toward



attack by cellular nucleophiles. On this basis, activated oxiranes may be useful antineoplastic agents. Although the activated oxiranes *cis*-**8a** and *trans*-**9a** reacted rapidly with pyrrolidine at 25° to yield *threo*-**10** and *erythro*-**11** respectively, the 2,3-epoxypropionitriles **6-9** were inactive in the P388 Lymphocytic Leukemia screen. The lack of tumor inhibiting activity for activated oxiranes **6-9** is likely due to their inability to act as biological alkylating agents.

EXPERIMENTAL

Melting points were determined with a Büchi capillary apparatus and are uncorrected. Nuclear magnetic resonance spectra were determined in deuteriochloroform (unless otherwise noted) with TMS as internal standard with a Varian EM-360A spectrometer. Infrared spectra (potassium bromide unless otherwise noted) were taken on a Unicam SP-1000 or Perkin-Elmer 267 spectrometer. Mass spectra were measured with an AEI-MS-12 mass spectrometer. Preparative high pressure liquid chromatography was performed using a Water's Prep LC/System 500A using Prep Pak-500 silica cartridges.

Cis-3-(2-Pyridinyl)-2,3-epoxypropionitrile (**6a**) and *Trans*-3-(2-Pyridinyl)-2,3-epoxypropionitrile (**7a**). Procedure A.

A solution of potassium *t*-butoxide, prepared by dissolution of potassium (3.0 g) in dry *t*-butyl alcohol (75 ml), was added dropwise during 90 minutes to a solution of 2-pyridinecarboxaldehyde (**5a**, 8.02 g, 75 mmol) and chloroacetonitrile (5.62 g, 75 mmol) with stirring and cooling at such a rate that the reaction temperature did not exceed 10°, under a nitrogen atmosphere. The reaction was allowed to proceed for an additional 1 hour, at which time tlc indicated the absence of **5a**. The *t*-butyl alcohol was removed *in vacuo* and 75 ml water was added to the residue. Extraction with ether (4 x 50 ml), drying (sodium sulfate) and removal of the solvent *in vacuo* gave a solid (6.5 g) which was partially purified by elution from a 5 x 30 cm silica gel column with ether as eluant to afford a mixture (6 g) of **6a** and **7a**. Preparative hplc using hexane-ether (1:9 v/v) as eluant at a flow rate of 250 ml min⁻¹ gave **7a** (3 g, 27%) in the 1100-1500 ml fraction and **6a** (2.5 g, 23%) in the 1700-2500 ml fraction. Stereoisomer **6a** (oil) had ir (neat): 2280 (CN), 1225 (oxirane) cm⁻¹; ¹H nmr: δ 3.94 (d, J_{2,3} = 4 Hz, 1H, H₂), 4.2 (d, J_{2,3} = 4 Hz, 1H, H₃),

7.25-7.65 (m, 2H, pyridinyl H₃, H₅), 7.8 (d, J_{4,5} = 8.5 Hz of d, J_{3,4} = 7 Hz of d, J_{4,6} = 2 Hz, 1H, H₄), 8.68 (d, J_{5,6} = 5 Hz of d, J_{4,6} = 2 Hz, 1H, H₆). Stereoisomer **7a** had mp 54°; ir: 2240 (CN), 1200 (oxirane) cm⁻¹; ¹H nmr: δ 3.92 (d, J_{2,3} = 2 Hz, 1H, H₂), 4.4 (d, J_{2,3} = 2 Hz, 1H, H₃), 7.1-7.45 (m, 2H, H₃, H₅), 7.76 (d, J_{4,5} = 8.5 Hz of d, J_{3,4} = 7 Hz of d, J_{4,6} = 2 Hz, 1H, H₄), 8.6 (d, J_{5,6} = 5 Hz of d, J_{4,6} = 2 Hz, 1H, H₆).

Anal. Calcd. for C₈H₈N₂O: C, 65.75; H, 4.10; N, 19.17. Found: C, 65.51; H, 4.30; N, 18.99.

Cis-3-(Pyridinyl)-2,3-epoxypropionitrile (**6a**) and *Trans*-3-(3-Pyridinyl)-2,3-epoxypropionitrile (**7b**).

Reaction of 3-pyridinecarboxaldehyde (**5b**, 10.7 g, 100 mmol) with chloroacetonitrile (7.0 g, 100 mmol) in the presence of potassium *t*-butoxide (11.2 g, 100 mmol) as described in Procedure A afforded a mixture of **6b** and **7b** (3.25 g). Preparative hplc using hexane-ether (3:20 v/v) as eluant at a flow rate of 250 ml min⁻¹ afforded **7b** (2.9 g, 20%) in the 1200-1550 ml fraction and **6b** (2.5 g, 17%) in the 1800-2500 ml fraction. Stereoisomer **6b** (oil) had ir (neat): 2180 (CN), 1230 (oxirane) cm⁻¹; ¹H nmr: δ 3.98 (d, J_{2,3} = 4 Hz, 1H, H₂), 4.4 (d, J_{2,3} = 4 Hz, 1H, H₃), 7.5 (d, J_{4,5} = 8.5 Hz of d, J_{5,6} = 5 Hz, 1H, H₅), 7.84 (d, J_{4,5} = 8.5 Hz of d, J_{4,6} = 2 Hz of d, J_{2,4} = 2 Hz, 1H, H₄), 8.76 (d, J_{5,6} = 5 Hz, of d, J_{4,6} = 2 Hz, 1H, H₆), 8.94 (d, J_{2,4} = 2 Hz, 1H, H₂).

Anal. Calcd. for C₈H₈N₂O: C, 65.75; H, 4.10; N, 19.17. Found: C, 65.89; H, 4.22; N, 19.17.

Stereoisomer **7b** had mp 69°; ir: 2180 (CN), 1230 (oxirane) cm⁻¹; ¹H nmr: δ 3.58 (d, J_{2,3} = 2 Hz, 1H, H₂), 4.43 (d, J_{2,3} = 2 Hz, 1H, H₃), 7.4 (d, J_{4,5} = 8.5 Hz of d, J_{5,6} = 5 Hz, 1H, H₅), 7.65 (d, J_{4,5} = 8.5 Hz of d, J_{2,4} = 2 Hz, 1H, H₄), 8.72 (d, J_{2,4} = 2 Hz, 1H, H₃), 8.76 (d, J_{5,6} = 5 Hz of d, J_{4,6} = 2 Hz, 1H, H₆).

Cis-3-(1-Oxido-2-pyridinyl)-2,3-epoxypropionitrile (**8a**). Procedure B.

A solution of *m*-chloroperbenzoic acid (2.76 g of 85%, 137 mmol) in methylene chloride was added dropwise to a solution of **6a** (1.82 g, 125 mmol) in methylene chloride (15 ml) at 0° with stirring. The reaction mixture was stirred at 0° for 30 minutes, 1 hour at 25° followed by heating at reflux for 24 hours. The volume was reduced by 50% and the reaction mixture was cooled and filtered. Removal of the solvent from the filtrate gave a residue which was purified by elution from a neutral alumina column using methanol-chloroform (1:19 v/v) as eluant. The product (1.9 g) was recrystallized from chloroform-ether (1:4 v/v) to yield **8a** (1.7 g, 85%), mp 114°; ir: 2250 (CN), 1260 (*N*-oxide), 1230 (oxirane) cm⁻¹; ¹H nmr: δ 4.1 (d, J_{2,3} = 4 Hz, 1H, H₂), 4.95 (d, J_{2,3} = 4 Hz, 1H, H₃), 7.25-7.62 (m, 3H, 1-oxido-2-pyridinyl H₃, H₄, H₅), 8.4 (m, 1H, 1-oxido-2-pyridinyl H₆).

Anal. Calcd. for C₈H₈N₂O₂: C, 59.25; H, 3.70; N, 17.28. Found: C, 59.09; H, 3.74; N, 17.46.

Trans-3-(1-Oxido-2-pyridinyl)-2,3-epoxypropionitrile (**9a**).

Oxidation of **7a** (1.46 g, 100 mmol) with *m*-chloroperbenzoic acid (2.77 g of 85%, 110 mmol) as described by Procedure B afforded **9a** (1.25 g, 77%), mp 153°; ir: 2260 (CN), 1260 (*N*-oxide), 1210 (oxirane) cm⁻¹; ¹H nmr: δ 3.55 (d, J_{2,3} = 2 Hz, 1H, H₂), 4.98 (d, J_{2,3} = 2 Hz, 1H, H₃), 7.2-7.6 (m, 3H, 1-oxido-2-pyridinyl H₃, H₄, H₅), 8.28-8.52 (m, 1H, 1-oxido-2-pyridinyl H₆).

Anal. Calcd. for C₈H₈N₂O₂: C, 59.25; H, 3.70; N, 17.28. Found: C, 58.88; H, 3.76; N, 17.12.

Cis-3-(1-Oxido-3-pyridinyl)-2,3-epoxypropionitrile (**8b**).

Oxidation of **6b** (1.46 g, 100 mmol) with *m*-chloroperbenzoic acid (2.22 g of 85%, 110 mmol) as described by Procedure B afforded **8b** (1.2 g, 74%), mp 125°; ¹H nmr: δ 3.92 (d, J_{2,3} = 4 Hz, 1H, H₂), 4.3 (d, J_{2,3} = 4 Hz, 1H, H₃), 7.3-7.5 (m, 2H, 1-oxido-3-pyridinyl H₄, H₅), 8.15-8.5 (m, 2H, 1-oxido-3-pyridinyl H₂, H₆).

Anal. Calcd. for C₈H₈N₂O₂: C, 59.25; H, 3.70; N, 17.28. Found: 58.89; H, 3.86; N, 17.16.

Trans-3-(1-Oxido-3-pyridinyl)-2,3-epoxypropionitrile (**9b**).

Reaction of **7b** (1.09 g, 75 mmol) with *m*-chloroperbenzoic acid (1.65 g of 85%, 82 mmol) as described by Procedure B yielded **9b** (0.7 g, 58%), mp 118°; ir: 2250 (CN), 1280 (*N*-oxide) cm^{-1} ; ^1H nmr (perdeuterio-methanol): δ 3.72 (d, $J_{2,3} = 2$ Hz, 1H, H_2), 4.38 (d, $J_{2,3} = 2$ Hz, 1H, H_3), 7.2-7.36 (m, 2H, 1-oxido-3-pyridinyl H_4 , H_5), 7.93-8.15 (m, 2H, 1-oxido-3-pyridinyl H_2 , H_6).

Anal. Calcd. for $\text{C}_8\text{H}_6\text{N}_2\text{O}_2$: C, 59.25; H, 3.70; N, 17.28. Found: C, 58.92; H, 3.84; N, 16.88.

Threo-2-(1-Pyrrolidino)-3-hydroxy-3-(1-oxido-2-pyridinyl)propionitrile (**10**).

Reaction of *cis*-**8a** (0.324 g, 2 mmol) with pyrrolidine (0.426 g, 6 mmol) at 25° for 15 minutes and removal of excess pyrrolidine *in vacuo* gave a semi-solid. Recrystallization from acetone gave **10** (0.40 g, 86%), mp 138°; ir: 2260 (CN), 1255 (*N*-oxide) cm^{-1} ; ^1H nmr (deuterio-chloroform + $\text{DMSO}-d_6$): δ 1.45-2.0 (m, 4H, pyrrolidino H_3 , H_4), 2.5-3.0 (m, 4H, pyrrolidino H_2 , H_5), 5.0 (d, $J_{2,3} = 6$ Hz, 1H, H_2), 5.4 (d, $J_{2,3} = 6$ Hz, 1H, H_3), 6.3-6.7 (br s, 1H, OH, exchanges with deuterium oxide), 7.3-7.9 (m, 3H, 1-oxido-2-pyridinyl H_3 , H_4 , H_5), 8.32 (d, $J_{5,6} = 6$ Hz of d, $J_{4,6} = 2$ Hz, 1H, 1-oxido-2-pyridinyl H_6).

Anal. Calcd. for $\text{C}_{12}\text{H}_{15}\text{N}_3\text{O}_2$: C, 61.80; H, 6.43; N, 18.02. Found: C, 61.80; H, 6.43; N, 18.07.

Erythro-2-(1-Pyrrolidino)-3-hydroxy-3-(1-oxido-2-pyridinyl)propionitrile (**11**).

Reaction of **9a** (0.324 g, 2 mmol) with pyrrolidine (0.426 g, 6 mmol) at 25° for 15 minutes and removal of the excess pyrrolidine *in vacuo* gave a semi-solid which on recrystallation from acetone gave **11** (0.38 g, 82%), mp 142°; ir: 2265 (CN), 1255 (*N*-oxide) cm^{-1} ; ^1H nmr (deuterio-chloroform + $\text{DMSO}-d_6$): δ 1.64-1.95 (m, 4H, pyrrolidino H_3 , H_4), 2.65-3.0 (m, 4H, pyrrolidino H_2 , H_5), 4.54 (d, $J_{2,3} = 4$ Hz, 1H, H_2), 5.4 (d, $J_{2,3} = 4$ Hz, 1H, H_3), 6.5 (br s, 1H, OH, exchanges with deuterium oxide), 7.3-7.85 (m, 3H, 1-oxido-2-pyridinyl H_3 , H_4 , H_5), 8.3 (d, $J_{5,6} = 6$ Hz of d, $J_{4,6} = 2$ Hz, 1H, 1-oxido-2-pyridinyl H_6).

Anal. Calcd. for $\text{C}_{12}\text{H}_{15}\text{N}_3\text{O}_2$: C, 61.80; H, 6.43; N, 18.02. Found: C, 61.67; H, 6.40; N, 17.98.

Antitumor Screening.

The screening was performed by the Drug Evaluation Branch of the NCI using the P388 Lymphocytic screen. A once daily maximum non-toxic dose (12.5-400 mg/kg range) in saline was administered by ip injection to mice for a total of nine doses. The % T/C (% T/C = treated/control $\times$ 100) was calculated for the different doses administered. Compounds **7a** (12.5 mg/kg), **7b** (400 mg/kg), **8a** (25 mg/kg), **8b** (50 mg/kg), **9a** (12.5 mg/kg) and **9b** (125 mg/kg) were considered to be inactive since the % T/C remained close to 100 for all compounds tested.

Acknowledgement.

We are grateful to the Medical Research Council of Canada (Grant MT-4888) for financial support of this work and to the Alberta Heritage Foundation for Medical Research for a fellowship to one of us (K.C.A.).

REFERENCES AND NOTES

- [1] J. R. Dimmock, L. M. Smith and P. J. Smith, *Can. J. Chem.*, **58**, 984, (1980).
- [2] A. C. Sartorelli, K. C. Agrawal, B. A. Booth, J. Pittman, D. G. Bartholomew and A. D. Broom, *J. Med. Chem.*, **19**, 830 (1976); K. C. Agrawal and A. C. Sartorelli, *J. Med. Chem.*, **21**, 218 (1978); W. Loh, L. A. Cosby and A. C. Sartorelli, *J. Med. Chem.*, **23**, 631 (1980).
- [3] D. A. Shiba, J. A. May, Jr. and A. C. Sartorelli, *Cancer Res.*, **43**, 2023 (1983); D. A. Shiba, L. A. Cosby and A. C. Sartorelli, *Cancer Res.*, **44**, 5707 (1984).
- [4] T. Satoh, Y. Kaneko, T. Izawa, K. Sakata and K. Yamakawa, *Bull. Chem. Soc. Japan*, **58**, 1983 (1985); T. Satoh, T. Kumagawa and K. Yamakawa, *Bull. Chem. Soc. Japan*, **58**, 2849 (1985).
- [5] A. Benderly, G. B. Fuller, E. E. Knaus and K. Redda, *Can. J. Chem.*, **56**, 2673 (1978); K. Avasthi and E. E. Knaus, *J. Heterocyclic Chem.*, **18**, 375 (1981).
- [6] H. Tucker, *J. Org. Chem.*, **44**, 2943 (1979).
- [7] D. A. Koechel, S. A. Smith and E. J. Cafruny, *J. Pharmacol. Exp. Ther.*, **203**, 272 (1977).
- [8] C. H. Lantz, J. Larner, R. M. Schubert, G. A. Howe and S. M. Kupchan, *Cancer Biochem. Biophys.*, **1**, 229 (1976).
- [9] R. L. Hanson, H. A. Lardy and S. M. Kupchan, *Science*, **168**, 378 (1970).